Published in:
Open Access
01-12-2008 | Commentary
Ex Vivo Metrics™, a preclinical tool in new drug development
Authors:
C Gerald Curtis, Kevin Bilyard, Hugo Stephenson
Published in:
Journal of Translational Medicine
|
Issue 1/2008
Login to get access
Abstract
Among the challenges facing translational medicine today is the need for greater productivity and safety during the drug development process. To meet this need, practitioners of translational medicine are developing new technologies that can facilitate decision making during the early stages of drug discovery and clinical development. Ex Vivo Metrics™ is an emerging technology that addresses this need by using intact human organs ethically donated for research. After hypothermic storage, the organs are reanimated by blood perfusion, providing physiologically and biochemically stable preparations. In terms of emulating human exposure to drugs, Ex Vivo Metrics is the closest biological system available for clinical trials. Early application of this tool for evaluating drug targeting, efficacy, and toxicity could result in better selection among promising drug candidates, greater drug productivity, and increased safety.